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 2 
Abstract 24 
Machine learning methods have been employed to make predictions in psychiatry from 25 
genotypes, with the potential to bring improved prediction of outcomes in psychiatric 26 
genetics; however, their current performance is unclear. We aim to systematically review 27 
machine learning methods for predicting psychiatric disorders from genetics alone and 28 
evaluate their discrimination, bias and implementation. Medline, PsychInfo, Web of Science 29 
and Scopus were searched for terms relating to genetics, psychiatric disorders and machine 30 
learning, including neural networks, random forests, support vector machines and boosting, 31 
on 10 September 2019. Following PRISMA guidelines, articles were screened for inclusion 32 
independently by two authors, extracted, and assessed for risk of bias. 63 full texts were 33 
assessed from a pool of 652 abstracts. Data were extracted for 77 models of schizophrenia, 34 
bipolar, autism or anorexia across 13 studies. Performance of machine learning methods 35 
was highly varied (0.48-0.95 AUC) and differed between schizophrenia (0.54-0.95 AUC), 36 
bipolar (0.48-0.65 AUC), autism (0.52-0.81 AUC) and anorexia (0.62-0.69 AUC). This is likely 37 
due to the high risk of bias identified in the study designs and analysis for reported results. 38 
Choices for predictor selection, hyperparameter search and validation methodology, and 39 
viewing of the test set during training were common causes of high risk of bias in analysis. 40 
Key steps in model development and validation were frequently not performed or 41 
unreported. Comparison of discrimination across studies was constrained by heterogeneity 42 
of predictors, outcome and measurement, in addition to sample overlap within and across 43 
studies. Given widespread high risk of bias and the small number of studies identified, it is 44 
important to ensure established analysis methods are adopted. We emphasise best 45 
practices in methodology and reporting for improving future studies. 46 
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Introduction 48 
Machine learning represents a contrasting approach to traditional methods for genetic 49 
prediction. It has increased in popularity in recent years following breakthroughs in deep 50 
learning [1–4], and the scaling-up of datasets and computing power. The ability to function 51 
in high dimensions and detect interactions between loci [5] without assuming additivity 52 
makes such methods an attractive option in statistical genetics, where the effects of myriad 53 
factors on an outcome is difficult to pre-specify. Calls to address the complexity of disorders 54 
like schizophrenia with machine learning have also become more frequent [6–8]. However, 55 
the predictive performance of machine learning methods in psychiatric genetics is unclear, 56 
and a recent review of clinical prediction models across various outcomes and predictors 57 
found them to be no more accurate than logistic regression [9]; it is therefore timely to 58 
review their predictive performance in psychiatry. 59 
 60 
Genome-wide association studies, genetic prediction and psychiatry have each been 61 
reviewed with respect to machine learning [10–16]. Recently, single nucleotide 62 
polymorphism (SNP)-based prediction has been reviewed across diseases [17]. However, 63 
psychiatry presents a distinct problem from somatic and neurological diseases as a result of 64 
genetic correlation between disorders [18] and the risk of class mislabelling due to biological 65 
heterogeneity that may underlie symptom-based diagnoses [19]. 66 
 67 
We systematically reviewed literature related to the question: what is the ability of machine 68 
learning (ML) methods to predict psychiatric disorders using only genetic data? We report 69 
discrimination, methodology and potential bias for diagnostic or prognostic models and 70 
compare to logistic regression (LR) and polygenic risk scores (PRS) where available. 71 
 4 
 72 
Materials and methods 73 
Search Strategy 74 
Medline via Ovid, PsychInfo, Web of Science and Scopus were searched for journal articles 75 
matching terms for machine learning, psychiatric disorders and genetics on 10th September 76 
2019. Searches were broad, with terms for psychiatric disorders including schizophrenia, 77 
bipolar, depression, anxiety, anorexia and bulimia, attention-deficit hyperactivity disorder, 78 
obsessive compulsive disorder, Tourette’s syndrome or autism. Terms for machine learning 79 
were also wide-ranging, including naïve Bayes, k-nearest neighbours (k-NN), penalised 80 
regression, decision trees, random forests, boosting, Bayesian networks, Gaussian 81 
processes, support vector machines and neural networks, but excluding regression methods 82 
without penalty terms, such as logistic regression. Searches were developed and conducted 83 
by MBS and were restricted to English language journal articles on humans, with no limits 84 
on search dates. Two authors (MBS, KC) independently reviewed all abstracts for inclusion. 85 
Full texts were assessed if either author had chosen to access them and independently 86 
screened against inclusion criteria. Where conflicts occurred a third author (VEP) was 87 
consulted as an arbiter. An example search for Medline (Ovid) is given in the supplementary 88 
(Table S1). 89 
 90 
Inclusion and Exclusion Criteria 91 
Studies were restricted to cohort, cross-sectional or case-control designs of individuals for 92 
binary classification of a single DSM or ICD-recognised psychiatric disorder compared to 93 
unaffected individuals, where only genotyping array, exome or whole-genome sequencing 94 
data were used as predictors. Studies based solely on gene expression were excluded, but 95 
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designs which made use of gene expression or functional annotations to inform models of 96 
genetic data were accepted. No further restriction was made on participants. Studies were 97 
excluded if they only predicted medication response, sub-groups within a psychiatric 98 
disorder or a psychiatric phenotype secondary to another disease. Studies were also 99 
considered ineligible if they had a clear primary aim of drawing inference at the expense of 100 
prediction, if they developed a novel statistical method or only made use of unsupervised or 101 
semi-supervised methods. The review was registered to PROSPERO in advance (registration 102 
number CRD42019128820). 103 
 104 
Extraction and Analysis 105 
A data extraction form was developed through discussion between all authors; items from 106 
the critical appraisal and data extraction for systematic reviews of prediction modelling 107 
studies (CHARMS) checklist [20] were included as-is or modified, and additional items were 108 
included based on expert knowledge and relevance to the review topic, with reference to 109 
the genetic risk prediction studies (GRIPS) statement [21] for items pertaining to genetic 110 
prediction studies (Table S2). The form was piloted with five publications, containing 40 111 
extracted ML models between them, and updated before being applied to all texts. 112 
 113 
The discrimination of machine learning methods was extracted independently by two 114 
authors (MBS, KC) as area under the receiver operating characteristic curve (AUC), or c-115 
statistic. Model performance measures for classification by accuracy, sensitivity and 116 
specificity were also extracted. 95% confidence intervals for validation were estimated for 117 
AUC using Newcombe's method [22]. Results were not meta-analysed due to sample 118 
overlap, present in at least half of studies (see Table S3), which cannot easily be accounted 119 
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for in the meta-analysis. Information on participants, predictors and model development 120 
and validation were also obtained. LR or PRS models were also extracted when present. 121 
Though LR can be considered a machine learning approach, for the purpose of this review 122 
we regard it as a contrasting method due to its widespread use in classic statistical analysis. 123 
The presence of LR and PRS as comparators was not made a requirement due to their 124 
sparsity in the literature.  125 
 126 
Risk of bias (ROB) and applicability were assessed using the prediction model risk of bias 127 
assessment tool (PROBAST) [23]. PROBAST consists of 20 questions designed to signal where 128 
ROB may be present in either the development or validation of a model across 4 categories: 129 
participants, predictors, outcome and analysis. These include, for instance, questions on 130 
how missingness or complexities in study design were handled. Information on handling of 131 
population structure, a common confound in genetic association studies, was also extracted 132 
to aid ROB assessment. Reporting of the systematic review follows the preferred reporting 133 
items for systematic reviews and meta-analyses (PRISMA) guidelines [24]. Extraction and 134 
ROB are detailed further in the supplementary. 135 
 136 
Results 137 
Selection 138 
1,241 publications were identified through searches in Ovid Medline, PsychInfo, Scopus and 139 
Web of Science which included restrictions to English language journal articles (Figure S1). 140 
After merging and removing duplicates, 652 studies were assessed for inclusion. Of these, 141 
63 full texts were assessed to determine eligibility. 14 publications were selected, with two 142 
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merged as publications included the same models on the same dataset. A final total of 13 143 
studies were selected for inclusion, containing 77 distinct machine learning models. 144 
 145 
Studies 146 
A wide range of machine learning methods were applied to schizophrenia (7 studies, 47% of 147 
models), bipolar disorder (5 studies, 39% of models), autism (3 studies, 10% of models) and 148 
anorexia (1 study, 4% of models) (Table 1), with no studies identified for the 6 remaining 149 
disorders. Single nucleotide polymorphisms (SNPs) were the most common source of 150 
genetic data. Copy number variants (CNVs) and PRSs were each incorporated in models 151 
from a single study, and exome-sequencing data formed the basis of two studies. Datasets 152 
typically consisted of publicly-available genome-wide association studies (GWAS); potential 153 
sample overlap was established for at least 7 studies (Table S3). Briefly, 3 studies [25–27] 154 
included controls for the 1958 Birth Cohort [28] or the UK Blood Service [29], 4 studies 155 
included controls from Knowledge Networks [25, 30–32], 2 studies used a Swedish 156 
population-based sample [32, 33], and 3 studies used the same dataset, or provided a 157 
common reference for part of the dataset [25, 30, 31]. The remaining 6 studies [34–40] 158 
either gave unclear information, reported no previous reference for the dataset, or used 159 
datasets which appear to be separate from other studies. Where samples overlap, all 160 
models included in the review are distinct, using different predictors or modelling 161 
approaches. Additional overlap or cryptic relatedness may be present between studies.  162 
 163 
Missingness was reported clearly in about half of all studies and models. When reported, it 164 
was most commonly handled by imputation after excluding genotypes with high 165 
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missingness. Studies also reported complete-case analysis and inclusion of missing values in 166 
coding of predictors (Table S4). 167 
 168 
Machine Learning Methods 169 
Support vector machines (SVMs) and neural networks were the most popular, followed by 170 
random forests and boosting. SVMs were split roughly equally between using a linear kernel 171 
(3 studies, 7 models), a radial basis function (RBF) kernel (3 studies, 6 models), or an 172 
unreported kernel (3 studies, 6 models). Authors applying neural networks most commonly 173 
used multilayer perceptrons (3 studies, 6 models), an RBF network (2 studies, 5 models) or 174 
restricted Boltzmann machines (RBMs; 1 study, 9 models), with linear networks, 175 
convolutional neural networks (CNNs) and embedding layers each used once. Weak learners 176 
in boosted models were mainly decision trees, with the exception of a method which 177 
combined feature selection with the boosting of RBF-SVMs in AdaBoost [35]. Penalised 178 
regression was employed alongside linear and non-linear methods as least absolute 179 
shrinkage and selection operator (LASSO; 3 studies, 4 models) or ridge regression (1 study, 2 180 
models). 51% of all models were implemented in R or WEKA; Matlab and Python were 181 
preferred for neural networks (Table S5). 182 
 183 
Risk of Bias 184 
Risk of bias was assessed for each model within each study (Figure S2). All models displayed 185 
risk of bias, mostly in relation to participants (study design and inclusion/exclusion criteria), 186 
outcome (standardised definition and assessment of outcomes) and analysis. Within-study 187 
ROB for participants was due to the use of case-control studies. Predictors were mostly 188 
rated to have unclear or low ROB; instances of high ROB were limited to predictors which 189 
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are unavailable at the point of model use. Outcome definitions or measurements often 190 
differed between cases and controls. 191 
 192 
Models displayed high ROB during analysis. This was often traced to inappropriate or 193 
unjustified handling of missingness and removal of enrolled participants prior to analysis, 194 
predictor selection using univariable methods and failure to account for overfitting. No 195 
studies reported calibration measures. In addition to PROBAST, information on population 196 
structure within studies was extracted (Table S6). Most studies did not illustrate genetic 197 
ancestry across all observations in the current publication using dimensionality reduction, 198 
and none reported any evaluation of the final trained model for bias due to population 199 
structure. However, 2 studies (18% of models) visualised principal components for a 200 
subsample or showed a table of reported ancestry for participants [31, 39]. Where ancestry 201 
was not addressed in a study, it was most often visualised in a referenced publication (55% 202 
of all models). 2 studies (13% of models) had no details or references which addressed 203 
genetic ancestry. 204 
 205 
Across-study ROB was not formally assessed. For schizophrenia, bipolar and autism, studies 206 
with smaller numbers of cases in the development set report AUC less often, instead 207 
preferring classification metrics such as accuracy, sensitivity and specificity. 208 
 209 
PROBAST encourages assessment of studies for applicability to the review question as this is 210 
often narrower than inclusion criteria [23]. Concern was identified for models in three 211 
studies [30, 39, 41]. All others demonstrated either low concern or unclear applicability. 212 
Reasons for concern were attributable to outcomes which combined closely-related 213 
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disorders, or the use of post-mortem gene expression data, whereas the review question 214 
focussed on models of single disorders with potential use in diagnosis or prognosis. 215 
 216 
Model Performance 217 
Over half of all models assessed discrimination using AUC (58% models). A wide range of 218 
classification metrics and measures of model fit were also reported (Table S7), with less 219 
than a quarter of models clearly reporting choosing a decision threshold a priori (Table S8). 220 
 221 
Around 79% of models, from 12 studies, reported some form of internal validation (Table 222 
S9). The majority of these were k-fold cross-validation (57% of all models; 8 studies), a 223 
resampling approach which involves testing a model on each of k independent partitions of 224 
a dataset, every time training on the remaining k-1 folds. 10-fold cross-validation (CV) was 225 
most commonly used, with just below half of all cross-validated models invoking repeats 226 
with different random splits. The remainder of studies using internal validation created a 227 
random split between training and testing sets (21% of all models; 5 studies), or applied 228 
apparent validation, where training and testing are both done on the whole sample [31]. A 229 
minority reported external validation (26% of models; 2 studies). Use of internal validation 230 
was not reported for 16 models from a single study [25], but for which geographic and 231 
temporal external validation was given. External validation was reported for one other 232 
study, but with partly overlapping participants between development and validation sets 233 
[32]. 234 
 235 
Model performance varied by choice of statistical method, sample size and number of 236 
predictors within studies (Table S10). Discrimination for models of schizophrenia (Figure 1) 237 
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was extremely varied (0.541-0.95 AUC), with the highest AUC from exome data using 238 
XGBoost (0.95 AUC) [33]. In this study, Trakadis et al. (2019) used counts of variants in each 239 
gene, after annotation and predictor selection, on participants with part-Finnish or Swedish 240 
ancestry [42]. Similarly high AUC (0.905 AUC) made use of multiple schizophrenia-associated 241 
PRS [32]. However, the authors identify the presence of both the development and 242 
validation samples in the psychiatric genomics consortium (PGC) GWAS used to generate 243 
the schizophrenia PRS [43], in addition to having overlapping controls between internal 244 
validation (model development) and external validation (replication) samples. All other 245 
schizophrenia models involved learning from SNPs [27, 30, 34–36], with the exception of 246 
Wang et al. (2018) [39] where gene expression data from post-mortem samples informed 247 
the weights in a conditional RBM trained on genotypes. 248 
 249 
Predictive ability for bipolar disorder (Figure 1) was consistently lower than for 250 
schizophrenia, frequently overlapping with chance (0.482-0.65 AUC). Models were trained 251 
on genotypes, excepting a study [38] using exome data to train a CNN as part of the Critical 252 
Assessment of Genome Interpretation (CAGI) competition [44], for which moderate 253 
discrimination was achieved (0.65 AUC). 254 
 255 
Significantly fewer models were reported for autism (8 models, 3 studies) and anorexia (3 256 
models, 1 study) (Figure 1). Varying predictive performance was illustrated in autism (0.516-257 
0.806 AUC). High AUC (0.806 AUC) was shown for a single prediction model [40], while 258 
models developed with a greater sample size by Engchuan et al. (2015) using CNVs were 259 
closer to or overlapping with chance (0.516-0.533 AUC) [37]. The only models predicting 260 
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anorexia nervosa had moderate discriminative ability between cases and controls (0.623-261 
0.693 AUC) [26]. 262 
 263 
Logistic regression and polygenic risk scores 264 
Three studies reported AUC for either logistic regression (5 models) or polygenic risk scores 265 
(12 models) alongside machine learning methods. PRS were weighted by summary statistics 266 
from a GWAS on the same disorder as the outcome and used as the sole predictor in a 267 
logistic regression model. Though discrimination shows some difference between model 268 
types, the number of studies for comparison is low and results are clustered by study and 269 
type of validation (Figure S3). 270 
 271 
Predictors 272 
Coding of predictors was mostly unclear or unreported (7 studies, 55% of models). Coding 273 
was unclear if it was implied through the description of the type of classifier or software but 274 
not clearly articulated for the reported study. PRS were continuous [32] while counts of 275 
variants-per-gene or genes-per-gene-set were used for exomes and CNVs respectively [33, 276 
37]. SNPs were coded under an additive model, a z-transformation of additive coding, or 277 
one-hot encoded (one predictor per genotype at a locus) (Table S11). GWAS summary 278 
statistics from external datasets were also used in the selection, weighting or combining of 279 
predictors (9 studies, 64% models; Table S12). 280 
 281 
Predictor selection was adopted by most (12, 73% of models) and limited to filter-based 282 
selection, used prior to modelling, and embedded selection, an integral part of the 283 
prediction model (Table S13). The latter involved LASSO regression, or ensembles and 284 
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hybrids of decision trees and decision tables, in addition to a modified AdaBoost [35]. Filters 285 
were based on internal or external univariable association tests (GWAS). Embedded and 286 
wrapper-based methods, which typically 'wrap' a model in forward or backward-selection, 287 
were both also used prior to any predictive modelling. Modification of predictors using 288 
information from the test set was the most common cause of information ‘leaking’ from the 289 
test set to the training set, a source of inflation in performance measures (Table S14). 290 
 291 
Sample size 292 
Total sample size was generally low where a single sample had been used, but higher if 293 
genotypes from publicly-available amalgamated datasets used in a GWAS had been 294 
downloaded (median 3486, range 40-11853) (Table S10). Number of events in development 295 
followed a similar pattern (median 1341, range 20-5554) as class imbalance was minimal 296 
(median 1, range 0.65-2.93, calculated as non-events over events). Around half of studies 297 
gave sufficient information to calculate events per variable (EPV) (median 0.69, range 298 
0.00063-74.6). It could not be calculated where the number of candidate predictors where 299 
not reported for models in 2 studies [25, 39]; approximations are given in the 300 
supplementary where reporting was unclear in a further 5 studies [26, 32–34, 36, 38] (Table 301 
S10). 302 
 303 
Hyperparameter Search 304 
Hyperparameter search was mostly unreported or unclear (41 models, 9 studies), with some 305 
models reported as having been used with default settings. Ambiguous reporting resulted 306 
from description of search and tuning for a specific model, with no clarity as to whether 307 
these conditions applied to other models in the study. Only 19% of models clearly reported 308 
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attempting different hyperparameters for the extracted models (Table S15). Studies also 309 
report non-standard final hyperparameters, such as uneven batch size in neural networks, 310 
or showed good accuracy for a model which is highly sensitive to tuning of crucial 311 
hyperparameters, yet few reported tuning (Table S16). It is therefore likely that most 312 
studies evaluated several hyperparameter choices but did not report this. 313 
 314 
Discussion 315 
All studies displayed high risk of bias in model development and validation with infrequent 316 
reporting of standard modelling steps. Performance measures consequently demonstrated 317 
a wide range of abilities to discriminate between cases and controls (0.482-0.95 AUC). These 318 
are likely optimistic owing to the high risk of bias identified through PROBAST and 319 
unaddressed sample overlap and population structure, as two studies showing the highest 320 
AUCs left these issues unresolved [32, 33]. Though potential bias and effective sample size 321 
limit overall interpretation of discrimination, low standards of model development, 322 
validation and reporting are a clear and consistent theme throughout all studies. Broad 323 
discrimination has also been observed for machine learning studies in cancer genomics [45]; 324 
more established fields with clearer predictor-response relationships, such as medical 325 
imaging, are much more consistent [46]. 326 
 327 
Issues relating to ROB often rest on distinctions in methodology between clinical prediction 328 
modelling, machine learning and genetic association studies. For instance, genetic studies 329 
most commonly employ a case-control design. Such studies are extremely useful for 330 
identifying genetic risk factors for rare outcomes, but are considered inadequate for 331 
prediction modelling as absolute risks cannot be estimated; instead, case-cohort, nested 332 
 15 
case-control, or prospective cohort designs are preferred [47]. Case-cohort and nested case-333 
control designs involve sampling from an existing cohort and can be used for prediction 334 
models if the sampling fraction in controls is accounted for in analysis [48]. To project the 335 
prediction to the whole population in case-control studies, positive and negative predictive 336 
values should be corrected in accordance with the disease prevalence in the population and 337 
ratio of cases and controls in the sample [49]. Similarly, univariable tests of association are 338 
applied routinely in GWAS, and are often used in selection of predictors for genetic 339 
prediction models. Their application in prediction modelling though is usually discouraged, 340 
as predictors may differ in their importance when evaluated in isolation as compared to 341 
when considered concurrently with other variables [50]. 342 
 343 
Lack of adherence to appropriate procedures for machine learning are also a common cause 344 
of a model being assessed as at high risk of bias. Standard model validation procedures 345 
were followed by some researchers; however, many 'leaked' information between training 346 
and testing sets through not applying predictor manipulations or selection in only the 347 
training set/fold, or using the testing set/fold to adjust model hyperparameters, which can 348 
impose significant bias on estimates of prediction performance [51].  349 
 350 
Most studies provided a measure of classification or discrimination for each model; none 351 
reported a measure of calibration. Model calibration compares observed and predicted 352 
probabilities of the outcome occurring, and is a crucial part of model development [52] 353 
which has been noted for its absence in genetic prediction literature [53]. Authors reporting 354 
only classification measures, such as accuracy, sensitivity or specificity, should also note that 355 
measures of discrimination are preferred as they use all the information over predicted 356 
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probabilities and delay any thresholding of risks to a more appropriate time. Of 357 
discrimination measures, the AUC is the most widely used in both machine learning and 358 
genetics [54, 55].  359 
 360 
Hyperparameter optimisation is an essential part of developing machine learning models as 361 
it determines how they navigate the bias-variance trade-off and learn from data [56]. It is 362 
therefore surprising that it was so often unreported or subject to a small number of manual 363 
experiments. Hyperparameters should be systematically searched to ensure a model is not 364 
over or under-fit. Randomised search has been shown to be more effective than grid search 365 
where two or more such parameters require tuning [57], though grid search is also 366 
recommended by practitioners for SVMs, often with an initial 'coarse' search followed by a 367 
more thorough exploration of a finer grid of values [58]. The importance of search is 368 
particularly relevant in domains where there are a small number of events per candidate 369 
predictor [59], such as genomics, as appropriate hyperparameter choices can reduce 370 
overfitting.  371 
 372 
Split-sample approaches were used by several studies, but should be avoided in favour of 373 
resampling methods such as bootstrapping or k-fold cross-validation [60]. The latter is an 374 
appropriate form of internal validation for traditional statistical methods; however, 375 
estimated prediction accuracies become overly-optimistic if done repeatedly, as when used 376 
for hyperparameter tuning through repeated rounds of CV. Nested cross-validation, where 377 
hyperparameters are optimised in an inner-fold and evaluated in the outer-fold, has been 378 
shown to give more realistic estimates [51, 61] but was not used in any studies. A single 379 
study presented both internal and external validation of models [32], for which a large drop 380 
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in performance is seen upon replication. Though partly due to sample overlap between the 381 
development set and the summary statistics used for generating a PRS, difficulty with 382 
replication is a wider issue in polygenic risk prediction. Risk scores for psychiatric disorders 383 
typically explain a small proportion of variance in a trait [62], with generalisation issues 384 
compounded by variants with small effect sizes and different allele frequencies between 385 
populations. Risk scores generated through machine learning methods have the potential to 386 
be more affected by these issues if appropriate modelling procedures are not followed. 387 
 388 
A source of bias not explicitly covered in PROBAST is population structure. Genetic ancestry 389 
has the potential to bias both associations [63, 64] and predictions [65, 66] from genetic 390 
data. Supervised machine learning methods have proved particularly sensitive in detecting 391 
ancestry [67–69]. Few researchers discussed visualising ancestry or reported exclusions, and 392 
none reported modelling adjustments, even when previous association studies on the same 393 
datasets had demonstrated stratification and included principal components as covariates. 394 
The extent of the bias introduced in these studies is not clear: evidence mostly relates to 395 
deliberately predicting populations in humans using ML or looking at bias in complex trait 396 
prediction from PRS. While the potential for population stratification to impact predictions 397 
is apparent, the method for dealing with it when using machine learning methods is not. 398 
Several techniques have been proposed, including modifications to random forests [70]; 399 
exclusions by, or inclusion of, principal components; and regressing-off the linear effects of 400 
principal components on SNPs before modelling (for example [71, 72]). Whether any 401 
combination of these is sufficient to reduce the effects of population stratification in non-402 
linear machine learning predictions has not been demonstrated. 403 
 404 
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General reporting guidelines for machine learning prediction models are yet to be 405 
developed [73], though recommendations for undertaking [74, 75] evaluating [76] or 406 
reporting [77] exist for machine learning in omics data, psychiatry and medicine 407 
respectively, in addition to reporting guidelines outside of machine learning [21, 78]. We 408 
encourage authors to report on implementation, samples, predictors, missingness, 409 
hyperparameters and handling of potential information leakage, and consult guidelines 410 
where needed. Finally, we advocate for machine learning methods to be reported alongside 411 
polygenic risk scores as a standard baseline model for comparison. The potential for 412 
machine learning methods to provide improved prediction has received heightened 413 
attention in recent years. Any such outcome cannot occur without adherence to standards 414 
for the development, validation and reporting of models. 415 
 416 
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Figure Legends 631 
Figure 1: discrimination for all models. n: number of cases in training set. Studies: a [35], b 632 
[40], c [34, 36], d [39], e [25], f [38], g [31], h [30], i [26], j [33], k [37], l [32], m [27]. 633 
*Accuracy calculated from confusion matrix. **SVM kernel not reported. †Modified 634 
architecture with intermediate phenotypes in training set only. ‡Modified architecture with 635 
intermediate phenotypes for training and test sets. ††Two-way MDR. ‡‡Three-way MDR. 636 
§Neural network embedding layer. 1,2,3,4Internal and external validation are shown for study 637 
l, where validations for the same model are denoted with the same number. AB: AdaBoost, 638 
BN: Bayesian networks, BFTree: best-first tree, CIF: conditional inference forest, cRBM: 639 
conditional restricted Boltzmann machine, CI: confidence interval, CNN: convolutional 640 
neural network, CNV: copy number variation, DTb: decision tables, DTNB: decision table 641 
naïve Bayes, DT: decision tree, EC: evolutionary computation, GE: gene expression, GBM: 642 
gradient boosting machine, k-NN: k-nearest neighbours, LASSO: least absolute shrinkage 643 
and selection operator, LNN: linear neural network, MDR: multifactor dimensionality 644 
reduction, MLP: multi-layer perceptron, NB: naïve Bayes, NN: neural network, PRS: 645 
polygenic risk scores, RBF: radial basis function, RF: random forests, SNP: single nucleotide 646 
polymorphisms, SVM: support vector machine, XGB: extreme gradient boosting. 647 
 648 
  649 
 32 
Tables and Table Legends 650 
 651 
First Author (Year) Disorder Machine Learning Methods Data Models Comparators 
Aguiar-Pulido et al. 
(2010; 2013)1 
Schizophrenia AdaBoost, BFTree, DNTB, decision tables, SVM 
(kernel not reported), naïve Bayes, Bayesian 
networks, MDR, neural network (RBF, linear, 
perceptron), evolutionary computation 
SNPs 12  
Yang et al. (2010) Schizophrenia AdaBoost (of SVM (RBF)), SVM (RBF) SNPs 2  
Pirooznia et al. 
(2012) 
Bipolar Disorder Bayesian networks, random forest, neural 
network (RBF), SVM (kernel not reported) 
SNPs 16 PRS, LR 
Li et al. (2014) Bipolar 
Disorder, 
Schizophrenia 
LASSO, Ridge, SVM (linear) SNPs 6  
Engchuan et al. 
(2015) 
Autism Neural network (perceptron), SVM (Linear), 
random forest, CIF 
CNVs 4  
Acikel et al. (2016) Bipolar Disorder MDR, random forest, k-NN, naïve Bayes SNPs 5  
Guo et al. (2016) Anorexia 
nervosa 
LASSO, SVM (RBF), GBM SNPs 3  
Laksshman et al. 
(2017) 
Bipolar Disorder Decision tree, random forest, neural network 
(CNN) 
Exomes 3  
Chen et al. (2018) Schizophrenia Neural network (perceptron) PRS 4 PRS, LR 
Wang et al. (2018) Schizophrenia, 
Bipolar 
Disorder, 
Autism 
Neural networks (cRBM) SNPs, 
gene 
expression 
9 LR 
Ghafouri-Fard et al. 
(2019) 
Autism Neural network (with embedding layer) SNPs 1  
Trakadis et al. 
(2019) 
Schizophrenia LASSO, random forest, SVM (kernel not 
reported), GBM (XGBoost) 
Exomes 4  
Vivian-Griffiths et al. 
(2019) 
Schizophrenia SVM (linear, RBF) SNPs 8 PRS 
 652 
Table 1: overview of studies. 1Merged in extraction [34, 36]. BFTree: best-first decision tree, 653 
CIF: conditional inference forest, cRBM: conditional restricted Boltzmann machine, CNN: 654 
 33 
convolutional neural network, DNTB: Decision table naïve Bayes, GBM: gradient boosting 655 
machine, k-NN: k-nearest neighbours, LASSO: least absolute shrinkage and selection 656 
operator, LR: logistic regression, MDR: multifactor dimensionality reduction, PRS: polygenic 657 
risk score, RBF: radial basis function, SVM: support vector machine. 658 
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